NDRA
NASDAQENDRA Life Sciences Inc.
Website
News25/Ratings0
Price$5.35+0.83 (+18.36%)
2026-01-162026-04-22
News · 26 weeks300%
2025-10-262026-04-19
Mix1490d
- Insider7(50%)
- SEC Filings4(29%)
- Other3(21%)
Latest news
25 items- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 10-K filed by ENDRA Life Sciences Inc.10-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. The Company intends to continue executing on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder ValueBoard to evaluate a range of alternatives while continuing to support core business priorities ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company. E
- INSIDERChief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERChief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- PRENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient CareAchieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad
- INSIDERDirector Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERDirector Harsh Michael was granted 60,324 shares, increasing direct ownership by 1,120% to 65,710 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERChief Financial Officer Jacroux Richard was granted 20,000 shares (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERDirector Basenese Lou was granted 60,324 shares, increasing direct ownership by 1,120% to 65,709 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- INSIDERChief Executive Officer Tokman Alexander Y was granted 75,000 shares, increasing direct ownership by 1,500,000% to 75,005 units (SEC Form 4)4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial UseFeasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These thresholds separate mild, moderate and severe disease, are widely
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form SCHEDULE 13D filed by ENDRA Life Sciences Inc.SCHEDULE 13D - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 424B4 filed by ENDRA Life Sciences Inc.424B4 - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH BiomarkerTAEUS Liver demonstrates strong agreement with the industry's imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease ("MASLD") and metabolic dysfunction-associated steatohepatitis ("MASH"), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key biomarker of steatotic liver disease ("SLD"). The preliminary study res
- PRENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial ResultsENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease ("MASLD") and metabolic dysfunction associated steatohepatitis ("MASH"), today provided a business update and reported financial results for the three and nine months ended September 30, 2025. Business Update Completed private placement of up to $14.4 million. On October 23, 2025, the Company closed a private investment in public equity (PIPE) financing led by institutional investors. The PIPE generated gross proceeds of approximately $4.9 million before placement agent fees and expenses,
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Other Events8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 10-Q filed by ENDRA Life Sciences Inc.10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCAENDRA is converting static treasury assets into a dynamic rewards engine to support medical innovation ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease ("MASLD") and metabolic dysfunction associated steatohepatitis ("MASH"), today announced a significant step in its digital asset strategy with the commencement of staking its holdings of HYPE, the native token of the Hyperliquid ecosystem. This strategic move, guided by ARCA Investment Management, LLC, and secured by Anchorage Digital, is designed to maximize the utility and return of the Company's
- SECSEC Form S-3 filed by ENDRA Life Sciences Inc.S-3 - ENDRA Life Sciences Inc. (0001681682) (Filer)